Insulin and the insulin receptor collaborate to promote human gastric cancer

Abstract

Background Gastric adenocarcinoma is common and consequent mortality high. Presentation and mortality are increased in obese individuals, many of whom have elevated circulating insulin concentrations. High plasma insulin concentrations may promote, and increase mortality from, gastric adenocarcinoma. Tumour promotion activities of insulin and its receptor are untested in gastric cancer cells. Methods Tumour gene amplification and expression were computed from sequencing and microarray data. Associations with patient survival were assessed. Insulin-dependent signal transduction, growth, apoptosis and anoikis were analysed in metastatic cells from gastric adenocarcinoma patients and in cell lines. Receptor involvement was tested by pharmacological inhibition and genetic knockdown. RNA was analysed by RT-PCR and proteins by western transfer and immunofluorescence. Results INSR expression was higher in tumour than in normal gastric tissue. High tumour expression was associated with worse patient survival. Insulin receptor was detected readily in metastatic gastric adenocarcinoma cells and cell lines. Isoforms B and A were expressed. Pharmacological inhibition prevented cell growth and division, and induced caspase-dependent cell death. Rare tumour INS expression indicated tumours would be responsive to pancreatic or therapeutic insulins. Insulin stimulated gastric adenocarcinoma cell PI3-kinase/Akt signal transduction, proliferation, and survival. Insulin receptor knockdown inhibited proliferation and induced programmed cell death. Type I IGF receptor knockdown did not induce cell death. Conclusions The insulin and IGF signal transduction pathway is dominant in gastric adenocarcinoma. Gastric adenocarcinoma cell survival depends upon insulin receptor. That insulin has direct cancer-promoting effects on tumour cells has implications for clinical management of obese and diabetic cancer patients.

Association between insulin resistance, metabolic syndrome and its components and lung cancer: a systematic review and meta-analysis

“…The relevance of IR to cancer has been demonstrated in clinical studies. Insulin, as a peptide hormone that stimulates tissue accretion, has a cancer-promoting effect [ 78 , 79 ]. Karlstad et al demonstrated that insulin use increases the risk of lung cancer [ 80 ].…”

Metabolic Syndrome and Clinical Outcomes of Patients with Gastric Cancer: A Meta-Analysis

“…In a previous case-control study, early GC was associated with diastolic blood pressure, total cholesterol, fasting glucose, and the homeostasis model assessment of the insulin resistance (HOMA-IR), which directly showed an association between insulin resistance and GC 34 . In addition, a recent experimental study showed that insulin and insulin-like growth factor (IGF) signal transduction pathway was dominant in gastric adenocarcinoma and responsible for the proliferation and survival of cancer cells 35 . Similarly, markers of activated IGF pathways have been shown to be prognostic factors for patient with GC 36 , which may be alternative evidence that hyperinsulinemia and insulin resistance are related with poor prognosis of patients with GC.…”

The role of insulin and incretin-based drugs in biliary tract cancer: epidemiological and experimental evidence

“…In addition to the observational evidence, many experimental studies provided solid confirmation of the positive relationship between insulin and cancer. Saisana et al reported that insulin has direct tumor-promoting effects on the gastric adenocarcinoma cells [ 56 ]. In the case of breast cancer, evidence revealed that insulin stimulates the proliferation of some human breast cancer cell lines in vitro by activating both the PI3K/Akt and the MAPK signaling pathways [ 57 ].…”